Reply to J.-H. Choi et al

Comment

Thomas Bachelot et al. J Clin Oncol. 2013.

. 2013 Feb 1;31(4):511.

doi: 10.1200/JCO.2012.46.7399.

No abstract available

Comment on

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Bachelot T, et al. J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7. J Clin Oncol. 2012. PMID: 22565002 Clinical Trial.
Appropriate design of prospective studies.
Choi JH, Jung SH. Choi JH, et al. J Clin Oncol. 2013 Feb 1;31(4):510-1. doi: 10.1200/JCO.2012.46.0980. Epub 2012 Dec 26. J Clin Oncol. 2013. PMID: 23269994 No abstract available.